Overview
Below are the details for the FACT-RNT measure.
MEASURE NAME:
Functional Assessment of Cancer Therapy – Radionuclide Therapy (FACT-RNT)
VERSION:
1
NUMBER OF ITEMS:
15
PATIENT POPULATION:
Patients receiving radionuclide therapy (RNT) for prostate cancer aged 18 years and older
RECALL PERIOD:
Past 7 days
RESPONSE SCALE:
5 point Likert-type scale
DATA COLLECTION:
Paper and electronic
ADMINISTRATION:
Self-administration and interview when applicable
SUBSCALE DOMAINS:
RNT
TIME FOR COMPLETION:
5-10 minutes
SCORING:
Manual scoring template, total score possible.
RELATED MEASURES:
Language Availability
Available translations of the FACT-RNT can be obtained by registering for permission. Users are not permitted to translate the FACT-RNT without permission from FACIT.org. Permission from FACIT.org to translate the FACT-RNT may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system.
Please contact us for more information.
Licensing
Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained.
Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use.
To license an available version of this measure for commercial or non-commercial use, please complete our registration form. All of the information provided in the form will be kept strictly confidential. For questions, please contact us.
Selected References
Gudenkauf LM, Chavez M, Maconi ML, Geiss C, Seyedroudbari A, Thin P, Hoogland AI, Nguyen K, Murthy V, Armstrong WR, Komrokji K, Oswald LB, Jim HSL, El-Haddad G, Fendler WP, Herrmann K, Cella D, Czernin J, Hofman MS, Dicker AP, Calais J, Tagawa ST, Gonzalez BD. Developing a novel patient reported outcomes measure for prostate cancer patients receiving radionuclide therapy. J Nucl Med. 2023 Jan 12:jnumed.122.264946. doi: 10.2967/jnumed.122.264946. Epub ahead of print. PMID: 36635088.
Related Measures